These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20701065)

  • 21. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
    Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for colorectal cancer by immunochemical fecal occult blood testing.
    Saito H
    Jpn J Cancer Res; 1996 Oct; 87(10):1011-24. PubMed ID: 8957057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic studies of immunologic fecal occult blood test for colorectal cancer.
    Iida Y; Munemoto Y; Miura S; Kasahara Y; Saito H; Mitsui T; Asada Y; Fukuoka K; Toya D; Tanaka N
    J Gastroenterol; 1995 Apr; 30(2):192-200. PubMed ID: 7773350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
    Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
    Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower specificity of occult-blood test on stool collected by digital rectal examination.
    Zhang B; Nakama H; Fattah AS; Kamijo N
    Hepatogastroenterology; 2002; 49(43):165-7. PubMed ID: 11949640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of three FOBT protocols for colorectal cancer screening in Chinese--a multicenter study].
    Li SR; Wang HH; Hu JC; Li N; Liu YL; Wu ZT; Zheng Y; Wang HH; Wu K; Ye H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):697-700. PubMed ID: 15932737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test.
    Tsuji Y; Gunji T; Sato H; Ono A; Ito T; Ohata K; Yamamichi N; Fujishiro M; Matsuhashi N; Koike K
    Dig Endosc; 2014 May; 26(3):424-9. PubMed ID: 24325675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the fecal microRNA test to the residuum from the fecal occult blood test.
    Yamazaki N; Koga Y; Yamamoto S; Kakugawa Y; Otake Y; Hayashi R; Saito N; Matsumura Y
    Jpn J Clin Oncol; 2013 Jul; 43(7):726-33. PubMed ID: 23677957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.
    Redwood D; Provost E; Asay E; Roberts D; Haverkamp D; Perdue D; Bruce MG; Sacco F; Espey D
    Prev Chronic Dis; 2014 Apr; 11():E56. PubMed ID: 24721216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
    Heresbach D; Chauvin P; Grolier J; Josselin JM
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity.
    Ransohoff DF; Lang CA
    JAMA; 1990 Jul; 264(1):76-8. PubMed ID: 2192093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.
    Chen CH; Yan SL; Yang TH; Chen SF; Yeh YH; Ou JJ; Lin CH; Lee YT; Chen CH
    J Clin Lab Anal; 2017 Jan; 31(1):. PubMed ID: 27390118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating gut microbiota profiles from archived fecal samples.
    Rounge TB; Meisal R; Nordby JI; Ambur OH; de Lange T; Hoff G
    BMC Gastroenterol; 2018 Nov; 18(1):171. PubMed ID: 30409123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance value of high risk factors in colorectal cancer screening in China.
    Meng W; Cai SR; Zhou L; Dong Q; Zheng S; Zhang SZ
    World J Gastroenterol; 2009 Dec; 15(48):6111-6. PubMed ID: 20027686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.